Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients. RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Data also demonstrated that none of the biological drugs selected for the comparison study proved to be anti-proliferative to any of the primary cell types assessed. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

JUNE 23, 2021

Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. billion, servicing nearly 340,000 active patients. In 2019, the island’s economy grew by 2.1% in real terms to £4.97 to reach 3.2

Programs 100

Programs Data Events Collective 100

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.

Patients 98

Patients Education Marijuana Therapy 98

SpeedWeed

MARCH 13, 2021

Almost 25% of patients with Parkinson’s disease reported that they had used cannabis in the prior six months in a survey from the Parkinson’s Foundation. Parkinson’s disease patients typically use pharmaceutical medications to treat their condition with varying degrees of success. More Than 1,000 PD Patients Surveyed.

Patients 52

Patients Treatment Therapy Sleep 52

The Joint Blog

APRIL 17, 2020

But as an older user-base with more complicated medical conditions continue to grow, it is important to understand how THC could adversely impact other co-administered medications. Medical cannabis is typically prescribed for patients with severe conditions including inflammatory conditions (e.g.,

Events 48

Events THC Chronic Pain Sleep 48

Cannabis Law Report

JULY 19, 2021

The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. billion by 2027.

Therapy 76

Therapy Data Research and Development Events 76

Veriheal

MAY 30, 2023

A new 2023 study published in BMJ Supportive & Palliative Care suggests that cannabis could be the answer millions of cancer patients have been looking for. of patients experience pain after curative treatment, while 66.4% of patients with advanced or metastatic cancer suffer from pain. Interestingly, 72.5%

Medicine 96

Medicine Treatment Patients Data 96

NORML

MARCH 20, 2019

NORML has previously written on the data showing a multi-directional association between cannabis and psychiatric illnesses, and we have cautioned that those predisposed to psychosis or other disorders may be at higher risk for adverse events. But it is not evidence that marijuana in any way causes the condition.

THC 280

THC Data Cannabis Events 280

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

JULY 29, 2021

Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. For more information visit: www.tetrabiopharma.com.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

DECEMBER 7, 2021

While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. Adverse mental events were reported as well, however, more research should be performed to assess well this outcome. 1.69, 95% CI [1.20–2.36])

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

JUNE 16, 2021

Genetic Screening Platform Technology and Data to Strengthen Entheon’s Psychedelic-Assisted Protocols. Lobo brings a highly experienced and specialized team of technology experts in the fields of genetics, diagnostics, data and analytics, as well as a fully operational 5,000 sq. Vancouver, British Columbia–(Newsfile Corp.

Research and Development 105

Research and Development Data Conditions Events 105

Cannabis Law Report

AUGUST 27, 2021

“This impressive group represents well-known leaders in the psychedelic and addiction fields and will help usher in a greater understanding of the science and data behind what we expect to be the most effective treatments for many mental health conditions ever available.”.

Research and Development 98

Research and Development Treatment Media Medicine 98

The Cannigma

OCTOBER 21, 2021

Still, many patients report that cannabis helps them to feel more in control of their symptoms, leading to important questions. Attention deficit hyperactivity disorder, or ADHD, is a condition characterized by behavioral symptoms such as inattentiveness, hyperactivity, impulsiveness. Can cannabis help with ADHD? What is ADHD?

Blood Pressure 137

Blood Pressure Treatment Patients Cannabis 137

Illinois News Joint

MAY 12, 2023

A third item states that, “The Department shall authorize a dispensing organization that has been unable to find a suitable location within the BLS Region in which it was awarded a license to transfer its Conditional Adult Use Dispensing Organization License to another BLS Region specified by the Department.” “BLS

Packaging 99

Packaging Agriculture Cannabis Cultivation 99

Illinois News Joint

JANUARY 5, 2023

In addition to three social equity adult use cannabis dispensaries that opened in 2022, 189 other conditional licensees are in the process of receiving full dispensary license from IDFPR. Our data from 2022 shows that we are well on our way towards making that idea a reality,” said Governor JB Pritzker.

Dispensary 76

Dispensary Recreational Cannabis Collective 76

CannaMD

SEPTEMBER 15, 2020

Current Florida medical marijuana patient? Patients suffering from cancer, epilepsy, chronic seizures, or muscle spasms could use low-THC cannabis products recommended by a licensed doctor. Doctors and patients had to register on the Compassionate Use Registry , an online database maintained by the Florida Department of Health.

Law 126

Law Marijuana Patients Treatment 126

Cannabis Law Report

JULY 9, 2021

The Horizons ETFs product family includes a broadly diversified range of solutions for investors of all experience levels to meet their investment objectives in a variety of market conditions. Horizons ETFs has over $19 billion of assets under management and 95 ETFs listed on major Canadian stock exchanges.

Data 105

Data Clinical Trials Decriminalization Hemp 105

The Cannigma

OCTOBER 9, 2021

Varied personal accounts of cannabis consumption causing a wide range of urinary effects have included but are not limited to: being unable to pee while feeling a strong urge to pee, peeing caused by laughter, and multiple sclerosis patients learning their cannabis medication also helps reduce the number of times they have to run to the bathroom.

Cannabinoids 86

Cannabinoids Consumption Patients Cannabis 86

Cannabis Law Report

JANUARY 23, 2022

Events like these afford us a glimpse into the future of research and medicine in this field. GVHD affects a significant portion of transplant patients, anywhere between 30% and 70% of patients depending on how closely the donor’s tissue matches with the patient. and 13.4%, respectively. Implications.

Research and Development 52

Research and Development Wellness and Beauty Patients CBD 52

Cannabis Law Report

OCTOBER 22, 2021

–The Company expects to hold a Research & Development event to review,these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO, CANADA – October 19, 2021 – Cybin Inc.

Research and Development 52

Research and Development Safety Media Data 52

Veriheal

MAY 3, 2022

The study was conducted by more than 10 researchers, with leads Dr. Jodi Gilman and Dr. Kevin Potter taking responsibility for the integrity and accuracy of the data. The study also said that the participants could continue their usual treatments or psychiatric care but did not specify which conditions the patients had.

Research and Development 95

Research and Development Clinical Trials Consumption Patients 95

Illinois News Joint

FEBRUARY 7, 2023

The Disparity and Availability Study’s purpose is to collect and analyze data and will report on whether discrimination exists in the Illinois cannabis industry. To learn about cannabis-friendly events in Illinois, visit here. To qualify and receive a medical patient card at a discounted rate, visit here. Constitution.

Agriculture 74

Agriculture Cannabis Policy Dispensary 74

Cannabis Law Report

NOVEMBER 18, 2021

NASDAQ: FORA), a provider of technology, analytics and data science driven solutions for the healthcare and cannabis industries, announced that Connecticut has chosen BioTrack as the track and trace system for the state’s Department of Consumer Protection Drug Control Division. NEWS RELEASE BY FORIAN. Newtown, PA | Forian Inc. About Forian.

Seed-To-Sale 52

Seed-To-Sale Data Research and Development Packaging 52

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. The immediate next steps are to submit data for ethics committee review and approval whereupon acceptance, further details will be provided. “A

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

JULY 9, 2021

We are excited to begin cultivation in West Virginia and be one step closer to providing relief to the patients who need it,” said Nicholas Vita, CEO of Columbia Care. Forward-looking statements may relate to future financial conditions, results of operations, plans, objectives, performance or business developments.

Research and Development 105

Research and Development Cultivation Seed-To-Sale Dispensary 105

Cannabis Law Report

MARCH 3, 2022

A representative of the Impact Forum told Marijuana Moment in an email that the event “is private and we do not issue transcripts, audio or video.”. “No Last week, at the Impact Forum event , the former president reportedly stressed the “need to have a national standard of the THC count of these products and what the tests show.”.

Media 52

Media CBD Events THC 52

Puff Puff Post

MARCH 2, 2020

Source: New Frontier Data). · Domestic quotas represent a further milestone in the Company’s stated timeline to bring the first medical cannabis products to market in Colombia, targeting patients with two priority conditions; chronic pain and nausea associated with chemotherapy. United States Disclaimer.

Extraction 52

Extraction THC Chronic Pain Cultivation 52

CannaMD

DECEMBER 9, 2020

Noting that the effects of oral administration of cannabis (edibles) can be less predictable that smoked or vaporized administration of products with similar levels of specific cannabinoids, the AHA cautions: Patients must be made aware that the onset of effects begins within 30 minutes to ?1 for men, 1.3%

Marijuana 111

Marijuana Research and Development Consumption Vaping 111

Cannabis Law Report

SEPTEMBER 20, 2021

Delic expects to open 15 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from psychedelic treatment for a variety of mental health conditions. Adding KWC will ensure our existing patients and many more in the future will receive the best medical treatment and care.

Treatment 52

Treatment Media Research and Development Patients 52

Dykema (Cannabis Law Blog)

MARCH 25, 2020

By that time, however, the Department of Public Health had only granted 650 registry identification cards to patients, well below anticipated participation levels. By this time, the State had roughly 2,800 patients, still far below expectations. At that point, Illinois had roughly 3,300 patients. By contrast, there are 18.4

Chronic Pain 40

Chronic Pain Conditions Patients CBD 40

Cannabis Law Report

APRIL 6, 2022

Greenlight continues this path in medical cannabis to bring its patients not only the quality and consistency they desire, but a unique experience that will keep them coming in. About Agrify (Nasdaq:AGFY). The forward-looking statements in this press release are only predictions.

Extraction 52

Extraction Cultivation Seed-To-Sale Events 52

Puff Puff Post

MARCH 10, 2020

InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Puff Puff Post

MARCH 2, 2020

Source: New Frontier Data). · Domestic quotas represent a further milestone in the Company’s stated timeline to bring the first medical cannabis products to market in Colombia, targeting patients with two priority conditions; chronic pain and nausea associated with chemotherapy. United States Disclaimer.

Extraction 40

Extraction THC Chronic Pain Cultivation 40